Trial reportScientific reports2025
Memantine treatment improves opioid-induced hyperalgesia symptoms: randomize clinical trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid-induced hyperalgesia (OIH) is a condition in which prolonged opioid use paradoxically increases sensitivity to noxious stimuli, resulting in heightened discomfort and diminished tolerance. This study aimed to investigate the clinical effects of Memantine in managing OIH symptoms in opioid-dependent patients. A randomized clinical trial involving 36 opioid-addicted patients diagnosed with opioid-induced hyperalgesia (OIH) was conducted between January and June 2022. Participants were randomly assigned to one of two groups: an intervention group receiving 10 mg/day of memantine, and a control group receiving placebo. The Cold Pressure Test (CPT) and Visual Analog Scale (VAS) were utilized to assess pain tolerance and intensity, respectively. The memantine group showed significantly increased cold pain tolerance at two and four weeks post-intervention (p = 0.005 and p < 0.001) and a significant reduction in pain intensity at two week (p = 0.001), though not at four weeks (p = 0.4536). Repeated measures ANOVA indicated significant within-subject effects of time for both CPT (F = 41.694, p = 0.001, η² = 0.558) and VAS (F = 69.065, p = 0.001, η² = 0.677), while between-group and interaction effects were not significant. This study offers preliminary support for the potential efficacy of 10 mg/day memantine in alleviating OIH symptoms, warranting further investigation to confirm these findings.Trial registration IRCT registration number IRCT20211112053045N1. Registration date 07/12/2021. IRCT URL https//irct.behdasht.gov.ir/trial/60,058. Ethical code IR.ZUMS.REC.1400.26.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.